ClinicalTrials.Veeva
Menu

Find clinical trials for Endometrial Cancer in Boston, MA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Ovarian Cancer
Breast Cancer
Triple Negative Breast Cancer
Ovarian Epithelial Carcinoma
Colorectal Cancer

Endometrial Cancer trials near Boston, MA, USA:

Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer

is evaluating a drug called Avelumab alone and in combination with Talazoparib or Axitinib as a possible treatment for recurrent or metastatic endometrial...

Active, not recruiting
Metastatic Endometrial Cancer
Drug: Avelumab
Drug: Axitinib

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Boston, Massachusetts, United States and 3 other locations

This research study is studying a drug combination as a possible treatment for endometrial cancer.The drugs involved in this study ...

Active, not recruiting
Endometrial Cancer
Drug: Pembrolizumab
Drug: IMGN853

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Boston, Massachusetts, United States and 2 other locations

The purpose of this research study is to see if the combination of study drugs avelumab and M1774 is effective and safe for participants with endometrial...

Enrolling
Endometrial Cancer
Recurrent Endometrial Carcinoma
Drug: Avelumab
Drug: M1774

Phase 2

Panagiotis Konstantinopoulos, MD, PhD

Boston, Massachusetts, United States and 1 other location

A Phase 2 Multi-center Open-label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer...

Enrolling
Endometrial Cancer
Endometrioid Endometrial Cancer
Drug: nab-sirolimus

Phase 2

Aadi Bioscience

Providence, Rhode Island, United States and 8 other locations

This research study is studying a combination of targeted therapies as a possible treatment for estrogen-receptor positive (ER+) endometrial ...

Active, not recruiting
Endometrial Cancer
Ovarian Cancer
Drug: Metformin
Drug: LY3023414

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Boston, Massachusetts, United States and 2 other locations

This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune check ...

Enrolling
Endometrial Cancer
Drug: Talazoparib
Drug: Bevacizumab

Phase 1, Phase 2

Alliance Foundation Trials

Boston, Massachusetts, United States and 20 other locations

A standard treatment for endometrial cancer is chemotherapy and pembrolizumab together followed by pembrolizumab maintenance for tw...

Enrolling
Endometrial Cancer
Recurrent Endometrial Cancer
Drug: Abemaciclib
Drug: Letrozole

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Boston, Massachusetts, United States and 5 other locations

letrozole in advanced stage, persistent or recurrent endometrioid endometrial cancer at 6 months. Treatment will continue until eit...

Active, not recruiting
Endometrial Cancer
Drug: Letrozole
Drug: Abemaciclib

Phase 2

Gynecologic Oncology Group (GOG)

Boston, Massachusetts, United States and 28 other locations

Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with plati...

Enrolling
Endometrial Cancer
Drug: Paclitaxel
Drug: Doxorubicin

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Worcester, Massachusetts, United States and 223 other locations

for maintenance selinexor in participants with advanced or recurrent endometrial cancer. Participants with primary stage IV or recu...

Active, not recruiting
Endometrial Cancer
Drug: Matching placebo for selinexor
Drug: Selinexor

Phase 3

Karyopharm Therapeutics
Karyopharm Therapeutics

Providence, Rhode Island, United States and 77 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems